Bay Street News

Oncolytics Biotech® Inc. Reports Data from Randomized Phase 2 Study of REOLYSIN® in Ovarian Cancer

–Intent-to-Treat Analysis Shows Statistically Significant Reduction in Tumour Burden as Measured by CA-125–

CALGARY, March 21, 2016 /CNW/ – Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY) (“Oncolytics” or the “Company”) today announced an update for a…